CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01351935
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:31.327313+00:00
Published At: 2019-11-08T00:00:00+00:00
Record Updated At: 2019-11-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["B Cell Non-Hodgkin\u0027s Lymphoma", "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-11-08"
protocolSection.identificationModule.nctId: "NCT01351935"
protocolSection.identificationModule.officialTitle: "Phase 1b, Escalating Dose Study of AVL-292, a Bruton\u0027s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin\u0027s Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom\u0027s Macroglobulinemia"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.